Jefferies Group LLC reaffirmed their buy rating on shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in a research report report published on Friday morning.
Several other equities research analysts have also recently weighed in on the company. Zacks Investment Research raised Karyopharm Therapeutics from a hold rating to a buy rating and set a $11.00 price target for the company in a research note on Thursday, July 6th. ValuEngine cut Karyopharm Therapeutics from a hold rating to a sell rating in a research note on Thursday, August 31st. Robert W. Baird reissued an outperform rating and issued a $15.00 price target on shares of Karyopharm Therapeutics in a research note on Tuesday, July 4th. Royal Bank Of Canada started coverage on Karyopharm Therapeutics in a research note on Thursday, September 14th. They issued an outperform rating and a $14.00 price target for the company. Finally, BidaskClub raised Karyopharm Therapeutics from a sell rating to a hold rating in a research note on Friday, August 25th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $15.38.
Karyopharm Therapeutics (NASDAQ KPTI) opened at 11.34 on Friday. The firm’s market capitalization is $534.54 million. Karyopharm Therapeutics has a 52-week low of $6.27 and a 52-week high of $14.63. The stock’s 50 day moving average price is $10.86 and its 200 day moving average price is $9.89.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.64) earnings per share for the quarter, meeting the consensus estimate of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. The company’s revenue was down 95.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.84) earnings per share. On average, equities analysts anticipate that Karyopharm Therapeutics will post ($2.62) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reiterated at Jefferies Group LLC” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/16/karyopharm-therapeutics-kpti-buy-rating-reiterated-at-jefferies-group-llc.html.
In other Karyopharm Therapeutics news, Director Mansoor Raza Mirza sold 2,882 shares of the stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $11.00, for a total value of $31,702.00. Following the transaction, the director now owns 2,882 shares in the company, valued at $31,702. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders sold 10,695 shares of company stock worth $118,950. Corporate insiders own 14.71% of the company’s stock.
A number of large investors have recently made changes to their positions in KPTI. Teachers Advisors LLC boosted its holdings in Karyopharm Therapeutics by 15.0% in the fourth quarter. Teachers Advisors LLC now owns 41,436 shares of the company’s stock worth $389,000 after acquiring an additional 5,419 shares in the last quarter. Nationwide Fund Advisors lifted its holdings in shares of Karyopharm Therapeutics by 175.8% in the first quarter. Nationwide Fund Advisors now owns 56,527 shares of the company’s stock valued at $726,000 after purchasing an additional 36,031 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Karyopharm Therapeutics by 103.9% in the first quarter. Russell Investments Group Ltd. now owns 74,882 shares of the company’s stock valued at $962,000 after purchasing an additional 38,158 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Karyopharm Therapeutics by 114.6% in the first quarter. Wells Fargo & Company MN now owns 43,606 shares of the company’s stock valued at $560,000 after purchasing an additional 23,284 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Karyopharm Therapeutics by 61.7% in the first quarter. Bank of New York Mellon Corp now owns 181,602 shares of the company’s stock valued at $2,332,000 after purchasing an additional 69,315 shares in the last quarter. Institutional investors and hedge funds own 58.97% of the company’s stock.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.